BFM
SCLN

Boothbay Fund Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Boothbay Fund Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,941
Closed -$163K – 1044
2016
Q3 		$163K Buy
+15,941
New +$174K 0.04% 583
2016
Q1 		– Sell
-15,390
Closed -$142K – 658
2015
Q4 		$142K Sell
15,390
-10,254
-40% -$85.8K 0.06% 476
2015
Q3 		$178K Buy
25,644
+7,893
+44% +$67.6K 0.08% 343
2015
Q2 		$174K Buy
17,751
+3,009
+20% +$27.4K 0.07% 343
2015
Q1 		$131K Buy
+14,742
New +$117K 0.09% 276

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Boothbay Fund Management's SCLN Position: Q4 2016 in Review

Boothbay Fund Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 15,941 shares — an estimated $163K sold.

Boothbay Fund Management first reported a position in SCLN in Q1 2015 and held it in 5 quarters. The position peaked at $178K in Q3 2015. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • Boothbay Fund Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Boothbay Fund Management sold 15,941 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $163K.
  • Boothbay Fund Management first reported a position in Sciclone Pharmaceuticals Inc in Q1 2015 and held it in 5 quarters.
  • Boothbay Fund Management's Sciclone Pharmaceuticals Inc position peaked at $178K in Q3 2015.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Boothbay Fund Management's 13F filing for Q4 2016, filed 15 Feb 2017.